aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2025-21-1-92-104ateroskleroz-1103Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSАртериальная тромбоэмболия и острый коронарный синдром у больных со злокачественными новообразованиями. Аналитический обзор. Часть 1Arterial thromboembolism and acute coronary syndrome in patients with malignant diseases. Analytical review. Part 1https://orcid.org/0009-0008-7674-9751КозловД. В.KozlovD. V.

Денис Владимирович Козлов, канд. мед. наук, врач-сердечно-сосудистый хирург

105187, г. Москва, ул. Фортунатовская, 1

Denis V. Kozlov, candidate of medical sciences, cardiovascular surgeon

1, Fortunatovskaya st., Moscow, 105187

kozlovden@mail.ruhttps://orcid.org/0009-0000-9735-8073ЗагорулькоА. И.ZagorulkoA. I.

Алексей Иванович Загорулько, канд. мед. наук, зав. отделением рентгенохирургических методов диагностики и лечения № 2, врач по рентгенэндоваскулярным диагностике и лечению, ассистент кафедры кардиологии, рентгенэндоваскулярных и гибридных методов диагностики и лечения

117152, г. Москва, Загородное шоссе, 18А, стр. 7

117198, г. Москва, ул. Миклухо-Маклая, 6

Alexey I. Zagorulko, candidate of medical sciences, head of the department of X-ray endovascular methods of diagnosis and treatment No. 2

18A, bld. 7, Zagorodnoye highw., Moscow, 117152

6, Miklukho-Maklaya st., Moscow, 117198

alexrus80@yandex.ruhttps://orcid.org/0009-0008-7473-6471НистратовГ. П.NistratovG. P.

Григорий Павлович Нистратов, канд. мед. наук, врач по рентгенэндоваскулярным диагностике и лечению отделения рентгенохирургических методов диагностики и лечения № 2

117152, г. Москва, Загородное шоссе, 18А, стр. 7

Grigory P. Nistratov, candidate of medical sciences, doctor of department of X-ray endovascular methods of diagnosis and treatment No. 2

18A, bld. 7, Zagorodnoye highw., Moscow, 117152

hyppokrat-g@mail.ruhttps://orcid.org/0009-0000-8486-3505РыковС. П.RykovS. P.

Станислав Павлович Рыков, врач по рентгенэндоваскулярным диагностике и лечению, отделения рентгенохирургических методов диагностики и лечения № 2

117152, г. Москва, Загородное шоссе, 18А, стр. 7

Stanislav P. Rykov, doctor at the department of X-ray endovascular methods of diagnosis and treatment No. 2

18A, bld. 7, Zagorodnoye highw., Moscow, 117152

stanislas.rykov@yandex.ruГосударственное бюджетное учреждение здравоохранения города Москвы «Городская клиническая больница им. Ф.И. Иноземцева Департамента здравоохранения города Москвы»State Budgetary Institution of Healthcare of the City of Moscow “City Clinical Hospital named after F.I. Inozemtsev of the Moscow City Health Department”Филиал «Онкологический центр № 1 Городской клинической больницы имени С.С. Юдина Департамента здравоохранения города Москвы»; Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов имени Патриса Лумумбы»Branch “Oncology Center No. 1 of the City Clinical Hospital named after S.S. Yudin of the Moscow City Health Department”; Federal State Autonomous Educational Institution of Higher Education “Peoples’ Friendship University of Russia named after Patrice Lumumba”Филиал «Онкологический центр № 1 Городской клинической больницы имени С.С. Юдина Департамента здравоохранения города Москвы»Branch “Oncology Center No. 1 of the City Clinical Hospital named after S.S. Yudin of the Moscow City Health Department”20253003202521192104Copyright © Козлов Д.В., Загорулько А.И., Нистратов Г.П., Рыков С.П., 20252025Козлов Д.В., Загорулько А.И., Нистратов Г.П., Рыков С.П.Kozlov D.V., Zagorulko A.I., Nistratov G.P., Rykov S.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/1103

Злокачественные новообразования и противоопухолевая терапия увеличивают риск развития артериальной тромбоэмболии, ишемического инсульта, инфаркта миокарда. Развитие артериальной тромбоэмболии у людей без онкологического анамнеза может быть предвестником еще не выявленных злокачественных новообразований. Понимание процесса артериальной тромбоэмболии является важным условием для правильного ведения пациентов с онкологическими заболеваниями в период лечения и после него с целью профилактики жизнеугрожающих осложнений.

Arterial thromboembolic complications are rare in cancer patients. Malignant neoplasms and antitumor therapy contribute to an increased risk of arterial thromboembolism, ischemic stroke, and myocardial infarction. The development of arterial thromboembolism in people without a history of cancer may be a harbinger of as yet undetected malignancies. Understanding the process of arterial thromboembolism is an important prerequisite for the proper management of patients with cancer during and after treatment in order to prevent life-threatening complications.

артериальная тромбоэмболияострая артериальная окклюзияартериальный тромбоззаболевание периферических артерийопухольэмболияракновообразованиеишемиязлокачественное новообразованиеинфаркт миокардаострый коронарный синдроминсультarterial thromboembolismarterial thromboembolicacute arterial occlusionarterial thrombosisperipheral artery diseasetumorembolismcancerneoplasmischemiamalignancymyocardial infarctionacute coronary syndromestrokeReferencesNavi B.B., Reiner A.S., Kamel H., Iadecola C., Elkind M.S., Panageas K.S., DeAngelis L.M. OC-02 – Risk of arterial thromboembolism in patients with breast cancer. Thromb. Res., 2016; 140, Suppl 1: S169. doi: 10.1016/S0049-3848(16)30119-0Navi B.B., Reiner A.S., Kamel H., Iadecola C., Elkind M.S., Panageas K.S., DeAngelis L.M. OC-02 – Risk of arterial thromboembolism in patients with breast cancer. Thromb. Res., 2016; 140, Suppl 1: S169. doi: 10.1016/S0049-3848(16)30119-0Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Elkind M.S.V., Panageas K.S., DeAngelis L.M. Risk of arterial thromboembolism in patients with cancer. J. Am. Coll. Cardiol., 2017; 70 (8): 926–938. doi: 10.1016/j.jacc.2017.06.047Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Elkind M.S.V., Panageas K.S., DeAngelis L.M. Risk of arterial thromboembolism in patients with cancer. J. Am. Coll. Cardiol., 2017; 70 (8): 926–938. doi: 10.1016/j.jacc.2017.06.047Grilz E., Königsbrügge O., Posch F., Schmidinger M., Pirker R., Lang I.M., Pabinger I., Ay C. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica, 2018; 103 (9): 1549–1556. doi: 10.3324/haematol.2018.192419Grilz E., Königsbrügge O., Posch F., Schmidinger M., Pirker R., Lang I.M., Pabinger I., Ay C. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica, 2018; 103 (9): 1549–1556. doi: 10.3324/haematol.2018.192419Mulder F.I., Horváth-Puhó E., van Es N., Pedersen L., Büller H.R., Bøtker H.E., Sørensen H.T. Arterial thromboembolism in cancer patients: a danish population-based cohort study. JACC CardioOncol., 2021; 3 (2): 205–218. doi: 10.1016/j.jac-cao.2021.02.007Mulder F.I., Horváth-Puhó E., van Es N., Pedersen L., Büller H.R., Bøtker H.E., Sørensen H.T. Arterial thromboembolism in cancer patients: a danish population-based cohort study. JACC CardioOncol., 2021; 3 (2): 205–218. doi: 10.1016/j.jac-cao.2021.02.007Qin Y., Zhang L., Liang X., Sun X., Wang N., Yuan M. Wang Q., Wu D. Venous and arterial thromboembolism in patients with metastatic lung cancer. Clin. Appl. Thromb. Hemost., 2023; 29: 10760296231159121. doi: 10.1177/10760296231159121Qin Y., Zhang L., Liang X., Sun X., Wang N., Yuan M. Wang Q., Wu D. Venous and arterial thromboembolism in patients with metastatic lung cancer. Clin. Appl. Thromb. Hemost., 2023; 29: 10760296231159121. doi: 10.1177/10760296231159121Cheong M.A., Leader A. Cancer and arterial thrombosis: therapeutic options. Res. Pract. Thromb. Haemost., 2024; 8 (3): 102393. https://doi.org/10.1016/j.rpth.2024.102393Cheong M.A., Leader A. Cancer and arterial thrombosis: therapeutic options. Res. Pract. Thromb. Haemost., 2024; 8 (3): 102393. https://doi.org/10.1016/j.rpth.2024.102393Xu Y., Mallity C., Collins E., Siegal D.M., Wang T.F., Carrier M. Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumor site: a systematic review and meta-analysis of randomized trials. Eur. Heart J. Cardiovasc. Pharmacother., 2024; pvae068. doi: 10.1093/ehjcvp/pvae068Xu Y., Mallity C., Collins E., Siegal D.M., Wang T.F., Carrier M. Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumor site: a systematic review and meta-analysis of randomized trials. Eur. Heart J. Cardiovasc. Pharmacother., 2024; pvae068. doi: 10.1093/ehjcvp/pvae068Zöller B., Ji J., Sundquist J., Sundquist K. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur. J. Cancer, 2012; 48 (1): 121–128. doi: 10.1016/j.ejca.2011.09.015Zöller B., Ji J., Sundquist J., Sundquist K. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur. J. Cancer, 2012; 48 (1): 121–128. doi: 10.1016/j.ejca.2011.09.015Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Tagawa S.T., Panageas K.S., DeAngelis L.M. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood, 2019; 133 (8): 781–789. doi: 10.1182/blood-2018-06-860874Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Tagawa S.T., Panageas K.S., DeAngelis L.M. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood, 2019; 133 (8): 781–789. doi: 10.1182/blood-2018-06-860874Starr D.S., Lawrie G.M., Morris G.C. Jr. Unusual presentation of bronchogenic carcinoma: Case report and review of the literature. Cancer, 1981; 47: 398–401. doi: 1002/1097-0142(19810115)47:2<398::aid-cncr2820470230>3.0.co;2-rStarr D.S., Lawrie G.M., Morris G.C. Jr. Unusual presentation of bronchogenic carcinoma: Case report and review of the literature. Cancer, 1981; 47: 398–401. doi: 1002/1097-0142(19810115)47:2<398::aid-cncr2820470230>3.0.co;2-rKhorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., Lyman G.H. Thromboembolism in hospitalized neutropenic cancer patients. J. Clin. Oncol., 2006; 24 (3): 484–490. doi: 10.1200/JCO.2005.03.8877Khorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., Lyman G.H. Thromboembolism in hospitalized neutropenic cancer patients. J. Clin. Oncol., 2006; 24 (3): 484–490. doi: 10.1200/JCO.2005.03.8877Marković M., Davidović L., Mikić A., Djorić P., Putnik S. Rare forms of peripheral arterial embolism: review of 11 cases. Vascular, 2005; 13: 222–229. doi: 10. 1258/rsmvasc.13.4.222Marković M., Davidović L., Mikić A., Djorić P., Putnik S. Rare forms of peripheral arterial embolism: review of 11 cases. Vascular, 2005; 13: 222–229. doi: 10. 1258/rsmvasc.13.4.222Navi B.B., Singer S., Merkler A.E., Cheng N.T., Stone J.B., Kamel H., Iadecola C., Elkind M.S., DeAngelis L.M. Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology, 2014; 83 (1): 26–33. doi: 10.1212/WNL.0000000000000539Navi B.B., Singer S., Merkler A.E., Cheng N.T., Stone J.B., Kamel H., Iadecola C., Elkind M.S., DeAngelis L.M. Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology, 2014; 83 (1): 26–33. doi: 10.1212/WNL.0000000000000539Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost., 2007; 5 (3): 632–634. doi: 10.1111/j.1538-7836.2007.02374.xKhorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost., 2007; 5 (3): 632–634. doi: 10.1111/j.1538-7836.2007.02374.xGon Y., Morishima T., Kawano T., Okazaki S., Todo K., Sasaki T., Mochizuki H., Miyashiro I. Arterial thromboembolism in Japanese patients with cancer: Incidence, predictors, and survival impact. JACC CardioOncol., 2024; 6 (2): 283–297. doi: 10.1016/j.jaccao.2024.01.006Gon Y., Morishima T., Kawano T., Okazaki S., Todo K., Sasaki T., Mochizuki H., Miyashiro I. Arterial thromboembolism in Japanese patients with cancer: Incidence, predictors, and survival impact. JACC CardioOncol., 2024; 6 (2): 283–297. doi: 10.1016/j.jaccao.2024.01.006Wang J., Kim Y.D., Kim C.H. Incidence and risk of various types of arterial thromboembolism in patients with cancer. Mayo Clin. Proc., 2021; 96 (3): 592–600. doi: 10.1016/j.mayocp.2020.05.045Wang J., Kim Y.D., Kim C.H. Incidence and risk of various types of arterial thromboembolism in patients with cancer. Mayo Clin. Proc., 2021; 96 (3): 592–600. doi: 10.1016/j.mayocp.2020.05.045Bollen E.C., van Duin C.J., van Noord J.A., Janssen J.G., Theunissen P.H. Tumor embolus in lung surgery. A case report and review of the literature. Eur. J. Cardiothorac. Surg., 1993; 7 (2): 104–106. doi: 10.1016/1010-7940(93)90190-mBollen E.C., van Duin C.J., van Noord J.A., Janssen J.G., Theunissen P.H. Tumor embolus in lung surgery. A case report and review of the literature. Eur. J. Cardiothorac. Surg., 1993; 7 (2): 104–106. doi: 10.1016/1010-7940(93)90190-mPrice L.C., Seckl M.J., Dorfmüller P., Wort S.J. Tumoral pulmonary hypertension. Eur. Respir. Rev., 2019; 28 (151): 180065. doi: 10.1183/16000617.0065-2018Price L.C., Seckl M.J., Dorfmüller P., Wort S.J. Tumoral pulmonary hypertension. Eur. Respir. Rev., 2019; 28 (151): 180065. doi: 10.1183/16000617.0065-2018Wang F., Gulati R., Lennon R.J., Lewis B.R., Park J., Sandhu G.S., Wright R.S., Lerman A., Herrmann J. Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute st-segment elevation myocardial infarction. Mayo Clin. Proc., 2016; 91 (12): 1680–1692. doi: 10.1016/j.mayocp.2016.06.029Wang F., Gulati R., Lennon R.J., Lewis B.R., Park J., Sandhu G.S., Wright R.S., Lerman A., Herrmann J. Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute st-segment elevation myocardial infarction. Mayo Clin. Proc., 2016; 91 (12): 1680–1692. doi: 10.1016/j.mayocp.2016.06.029Sundbøll J., Veres K., Horváth-Puhу E., Adelborg K., Sørensen H.T. Risk and prognosis of cancer after lower limb arterial thrombosis. Circulation, 2018; 138 (7): 669–677. doi: 10.1161/CIRCULATIONAHA.117.032617Sundbøll J., Veres K., Horváth-Puhу E., Adelborg K., Sørensen H.T. Risk and prognosis of cancer after lower limb arterial thrombosis. Circulation, 2018; 138 (7): 669–677. doi: 10.1161/CIRCULATIONAHA.117.032617Kaschwich M., Peters F., Hischke S., Rieß H.C., Gansel M., Marschall U., L’Hoest H., Heidemann F., Debus E.S., Acar L., Kreutzburg T., Behrendt C.A. Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease – a health insurance claims data analysis. Vasa, 2020; 49 (6): 493–499. doi: 10.1024/0301-1526/a000901Kaschwich M., Peters F., Hischke S., Rieß H.C., Gansel M., Marschall U., L’Hoest H., Heidemann F., Debus E.S., Acar L., Kreutzburg T., Behrendt C.A. Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease – a health insurance claims data analysis. Vasa, 2020; 49 (6): 493–499. doi: 10.1024/0301-1526/a000901Lee J.M., Yoon C.H. Acute coronary stent thrombosis in cancer patients: a case series report. Korean Circ. J., 2012; 42 (7): 487–491. doi: 10.4070/kcj.2012.42.7.487Lee J.M., Yoon C.H. Acute coronary stent thrombosis in cancer patients: a case series report. Korean Circ. J., 2012; 42 (7): 487–491. doi: 10.4070/kcj.2012.42.7.487Ganatra S., Sharma A., Levy M.S. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc. Interv., 2017; 10 (22): 2334–2337. doi: 10.1016/j.jcin.2017.06.068Ganatra S., Sharma A., Levy M.S. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc. Interv., 2017; 10 (22): 2334–2337. doi: 10.1016/j.jcin.2017.06.068Yu J., Li A., Laureano M., Crowther M. Frequency of arterial thromboembolism in populations with malignancies: A systematic review. Thromb. Res., 2019; 184: 16–23. doi: 10.1016/j.thromres.2019.10.004Yu J., Li A., Laureano M., Crowther M. Frequency of arterial thromboembolism in populations with malignancies: A systematic review. Thromb. Res., 2019; 184: 16–23. doi: 10.1016/j.thromres.2019.10.004Canale M.L., Bisceglia I., Lestuzzi C., Parrini I.; ANMCO Cardio-Oncology Task Force. Arterial thrombosis in cancer: spotlight on the neglected vessels. Anticancer Res., 2019; 39 (9): 4619–4625. doi: 10.21873/anticanres.13642Canale M.L., Bisceglia I., Lestuzzi C., Parrini I.; ANMCO Cardio-Oncology Task Force. Arterial thrombosis in cancer: spotlight on the neglected vessels. Anticancer Res., 2019; 39 (9): 4619–4625. doi: 10.21873/anticanres.13642Qi W.X., Shen Z., Tang L.N., Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit. Rev. Oncol. Hematol., 2014; 92 (2): 71–82. doi: 10.1016/j.critrev-onc.2014.04.004Qi W.X., Shen Z., Tang L.N., Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit. Rev. Oncol. Hematol., 2014; 92 (2): 71–82. doi: 10.1016/j.critrev-onc.2014.04.004McBane R.D. 2nd. Arterial thrombosis and cancer: implications for screening and risk modification. Mayo Clin. Proc., 2021; 96 (3): 526–528. doi: 10.1016/j.mayocp.2021.01.013McBane R.D. 2nd. Arterial thrombosis and cancer: implications for screening and risk modification. Mayo Clin. Proc., 2021; 96 (3): 526–528. doi: 10.1016/j.mayocp.2021.01.013Quartermaine C., Ghazi S.M., Yasin A., Awan F.T., Fradley M., Wiczer T., Kalathoor S., Ferdousi M, Krishan S., Habib A., Shaaban A., Kola-Kehinde O., Kittai A.S., Rogers K.A., Grever M., Ruz P., Bhat S., Dickerson T., Byrd J.C., Woyach J., Addison D. Cardiovascular toxicities of BTK Inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology stateof-the-art review. JACC CardioOncol., 2023; 5 (5): 570–590. doi: 10.1016/j.jaccao.2023.09.002Quartermaine C., Ghazi S.M., Yasin A., Awan F.T., Fradley M., Wiczer T., Kalathoor S., Ferdousi M, Krishan S., Habib A., Shaaban A., Kola-Kehinde O., Kittai A.S., Rogers K.A., Grever M., Ruz P., Bhat S., Dickerson T., Byrd J.C., Woyach J., Addison D. Cardiovascular toxicities of BTK Inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology stateof-the-art review. JACC CardioOncol., 2023; 5 (5): 570–590. doi: 10.1016/j.jaccao.2023.09.002Enderoff E., Kirschner P.A. Massive tumor embolism during pulmonary surgery. J. Thorac. Cardiovasc. Surg., 1962; 44: 528–535.Enderoff E., Kirschner P.A. Massive tumor embolism during pulmonary surgery. J. Thorac. Cardiovasc. Surg., 1962; 44: 528–535.Falanga A., Schieppati F., Russo D. Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer. Semin. Thromb. Hemost., 2015; 41 (7): 756–764. doi: 10.1055/s-0035-1564040Falanga A., Schieppati F., Russo D. Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer. Semin. Thromb. Hemost., 2015; 41 (7): 756–764. doi: 10.1055/s-0035-1564040Zwicker J.I., Liebman H.A., Neuberg D., Lacroix R., Bauer K.A., Furie B.C., Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer. Res., 2009; 15 (22): 6830–6840. doi: 10.1158/1078-0432.CCR-09-0371Zwicker J.I., Liebman H.A., Neuberg D., Lacroix R., Bauer K.A., Furie B.C., Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer. Res., 2009; 15 (22): 6830–6840. doi: 10.1158/1078-0432.CCR-09-0371Grover S.P., Mackman N. Tissue factor: An essential mediator of hemostasis and trigger of thrombosis. Arterioscler. Thromb. Vasc. Biol., 2018; 38 (4): 709–725. doi: 10.1161/Atvbaha.117.309846Grover S.P., Mackman N. Tissue factor: An essential mediator of hemostasis and trigger of thrombosis. Arterioscler. Thromb. Vasc. Biol., 2018; 38 (4): 709–725. doi: 10.1161/Atvbaha.117.309846Laridan E., Martinod K., de Meyer S.F. Neutrophil extracellular traps in arterial and venous thrombosis. Semin. Thromb. Hemost., 2019; 45 (1): 86–93. doi: 10.1055/s-0038-1677040Laridan E., Martinod K., de Meyer S.F. Neutrophil extracellular traps in arterial and venous thrombosis. Semin. Thromb. Hemost., 2019; 45 (1): 86–93. doi: 10.1055/s-0038-1677040Moschonas I.C., Tselepis A.D. The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. Atherosclerosis, 2019; 288: 9–16. doi: 10.1016/j.atherosclerosis.2019.06.919Moschonas I.C., Tselepis A.D. The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. Atherosclerosis, 2019; 288: 9–16. doi: 10.1016/j.atherosclerosis.2019.06.919Massberg S., Grahl L., von Bruehl M.L., Manukyan D., Pfeiler S., Goosmann C., Brinkmann V., Lorenz M., Bidzhekov K., Khandagale A.B., Konrad I., Kennerknecht E., Reges K., Holdenrieder S., Braun S., Reinhardt C., Spannagl M., Preissner K.T., Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat. Med., 2010; 16 (8): 887–896. doi: 10.1038/nm.2184Massberg S., Grahl L., von Bruehl M.L., Manukyan D., Pfeiler S., Goosmann C., Brinkmann V., Lorenz M., Bidzhekov K., Khandagale A.B., Konrad I., Kennerknecht E., Reges K., Holdenrieder S., Braun S., Reinhardt C., Spannagl M., Preissner K.T., Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat. Med., 2010; 16 (8): 887–896. doi: 10.1038/nm.2184Thеlin C., Demers M., Blomgren B., Wong S.L., von Arbin M., von Heijne A., Laska A.C., Wallén H., Wagner D.D., Aspberg S. NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb. Res., 2016; 139: 56–64. doi: 10.1016/j.thromres.2016.01.009Thеlin C., Demers M., Blomgren B., Wong S.L., von Arbin M., von Heijne A., Laska A.C., Wallén H., Wagner D.D., Aspberg S. NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb. Res., 2016; 139: 56–64. doi: 10.1016/j.thromres.2016.01.009Grover S.P., Hisada Y.M., Kasthuri R.S., Reeves B.N., Mackman N. Cancer therapy-associated thrombosis. Arterioscler. Thromb. Vasc. Biol., 2021; 41 (4): 1291– 1305. doi: 10.1161/ATVBAHA.120.314378Grover S.P., Hisada Y.M., Kasthuri R.S., Reeves B.N., Mackman N. Cancer therapy-associated thrombosis. Arterioscler. Thromb. Vasc. Biol., 2021; 41 (4): 1291– 1305. doi: 10.1161/ATVBAHA.120.314378Zhu J., Chen Y., Zhang Y., Wang W., Wang Y., Lu Zh., Zhang Yu., Lei H., Li D., Long B., Liu H. Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study. Cancer Med., 2023; 12: 118531–18541. doi: 10.1002/cam4.6455Zhu J., Chen Y., Zhang Y., Wang W., Wang Y., Lu Zh., Zhang Yu., Lei H., Li D., Long B., Liu H. Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study. Cancer Med., 2023; 12: 118531–18541. doi: 10.1002/cam4.6455Alexandre J., Salem J.E., Moslehi J., Sassier M., Ropert C., Cautela J., Thuny F., Ederhy S., Cohen A., Damaj G., Vilque J.P., Plane A.F., Legallois D., Champ-Rigot L., Milliez P., Funck-Brentano C., Dolladille C. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur. Heart J. Cardiovasc. Pharmacother., 2021; 7 (4): 312–320. doi: 10.1093/ehjcvp/pvaa037Alexandre J., Salem J.E., Moslehi J., Sassier M., Ropert C., Cautela J., Thuny F., Ederhy S., Cohen A., Damaj G., Vilque J.P., Plane A.F., Legallois D., Champ-Rigot L., Milliez P., Funck-Brentano C., Dolladille C. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur. Heart J. Cardiovasc. Pharmacother., 2021; 7 (4): 312–320. doi: 10.1093/ehjcvp/pvaa037Salem J.E., Manouchehri A., Bretagne M., Lebrun-Vignes B., Groarke J.D., Johnson D.B., Yang T., Reddy N.M., Funck-Brentano C., Brown J.R., Roden D.M., Moslehi J.J. Cardiovascular toxicities associated with ibrutinib. J. Am. Coll. Cardiol., 2019; 74 (13): 1667–1678. doi: 10.1016/j.jacc.2019.07.056Salem J.E., Manouchehri A., Bretagne M., Lebrun-Vignes B., Groarke J.D., Johnson D.B., Yang T., Reddy N.M., Funck-Brentano C., Brown J.R., Roden D.M., Moslehi J.J. Cardiovascular toxicities associated with ibrutinib. J. Am. Coll. Cardiol., 2019; 74 (13): 1667–1678. doi: 10.1016/j.jacc.2019.07.056Виценя М.В., Агеев Ф.Т., Гиляров М. Ю., Овчинников А. Г., Орлова Р. В., Полтавская М. Г. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO. Злокачественные опухоли, 2023; 13 (2): 86–111. doi: 10.18027/2224-5057-2023-13-3s2-2-86-111Vitsenya M.V., Ageev F.T., Gilyarov M.Yu., Ovchinnikov A.G., Orlova R.V., Poltavskaya M.G. Practical recommendations for the correction of cardiovascular toxicity of antitumor drug therapy. RUSSCO Practical recommendations. Malignant tumors, 2023; 13 (2): 86–111. (In Russ.)]. doi: 10.18027/2224-5057-2023-13-3s2-2-86-111Valent P., Hadzijusufovic E., Schernthaner G.H., Wolf D., Rea D., le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 2015; 125 (6): 901–906. doi: 10.1182/blood-2014-09-594432Valent P., Hadzijusufovic E., Schernthaner G.H., Wolf D., Rea D., le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 2015; 125 (6): 901–906. doi: 10.1182/blood-2014-09-594432Paris F., Fuks Z., Kang A., Capodieci P., Juan G., Ehleiter D., Haimovitz-Friedman A., Cordon-Cardo C., Kolesnik R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science, 2001; 293 (5528): 293–297. doi: 10.1126/science.1060191Paris F., Fuks Z., Kang A., Capodieci P., Juan G., Ehleiter D., Haimovitz-Friedman A., Cordon-Cardo C., Kolesnik R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science, 2001; 293 (5528): 293–297. doi: 10.1126/science.1060191Texakalidis P., Giannopoulos S., Tsouknidas I., Song S., Rivet D., Reiter E., Reavey-Cantwell J. Prevalence of carotid stenosis following radiotherapy for head and neck cancer: A systematic review and meta-analysis. Head Neck., 2020; 42 (5): 1077–1088. doi: 10.1002/hed.26102Texakalidis P., Giannopoulos S., Tsouknidas I., Song S., Rivet D., Reiter E., Reavey-Cantwell J. Prevalence of carotid stenosis following radiotherapy for head and neck cancer: A systematic review and meta-analysis. Head Neck., 2020; 42 (5): 1077–1088. doi: 10.1002/hed.26102Murphy E.S., Xie H., Merchant T.E., Yu J.S., Chao S.T., Suh J.H. Review of cranial radiotherapy-induced vasculopathy. J. Neurooncol., 2015; 122 (3): 421–429. doi: 10.1007/s11060-015-1732-2Murphy E.S., Xie H., Merchant T.E., Yu J.S., Chao S.T., Suh J.H. Review of cranial radiotherapy-induced vasculopathy. J. Neurooncol., 2015; 122 (3): 421–429. doi: 10.1007/s11060-015-1732-2Feldman S., Gupta D., Navi B.B., Grace Ho K.W., Willeit P., Devlin S., Bolton K.L., Arcila M.E., Mantha S. Tumor genomic profile is associated with arterial thromboembolism risk in patients with solid cancer. JACC CardioOncol., 2023; 5 (2): 246–255. doi: 10.1016/j.jaccao.2023.01.009Feldman S., Gupta D., Navi B.B., Grace Ho K.W., Willeit P., Devlin S., Bolton K.L., Arcila M.E., Mantha S. Tumor genomic profile is associated with arterial thromboembolism risk in patients with solid cancer. JACC CardioOncol., 2023; 5 (2): 246–255. doi: 10.1016/j.jaccao.2023.01.009Buijs J.T., Versteeg H.H. Genes and proteins associated with the risk for cancer-associated thrombosis. Thromb. Res., 2020; 191 Suppl 1: S43–S49. doi: 10.1016/S0049-3848(20)30396-0Buijs J.T., Versteeg H.H. Genes and proteins associated with the risk for cancer-associated thrombosis. Thromb. Res., 2020; 191 Suppl 1: S43–S49. doi: 10.1016/S0049-3848(20)30396-0Al-Samkari H., Leiva O., Dagogo-Jack I., Shaw A., Lennerz J., Iafrate A.J., Bendapudi P.K., Connors J.M. Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC. J. Thorac. Oncol., 2020; 15 (9): 1497–1506. doi: 10.1016/j.jtho.2020.04.033Al-Samkari H., Leiva O., Dagogo-Jack I., Shaw A., Lennerz J., Iafrate A.J., Bendapudi P.K., Connors J.M. Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC. J. Thorac. Oncol., 2020; 15 (9): 1497–1506. doi: 10.1016/j.jtho.2020.04.033Rak J., Milsom C., May L., Klement P., Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin. Thromb. Hemost., 2006; 32 (1): 54–70. doi: 10.1055/s-2006-933341Rak J., Milsom C., May L., Klement P., Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin. Thromb. Hemost., 2006; 32 (1): 54–70. doi: 10.1055/s-2006-933341Vavlukis M., Kotlar I., Chaparoska E., Antova E., Kedev S. Diffuse arterial thrombosis as a first manifestation of occult malignancy. Case Rep. Med., 2016; 2016: 1658392. doi: 10.1155/2016/1658392Vavlukis M., Kotlar I., Chaparoska E., Antova E., Kedev S. Diffuse arterial thrombosis as a first manifestation of occult malignancy. Case Rep. Med., 2016; 2016: 1658392. doi: 10.1155/2016/1658392Selvik H.A., Thomassen L., Bjerkreim A.T., Næss H. Cancer-associated stroke: The Bergen NORSTROKE study. Cerebrovasc. Dis. Extra, 2015; 5 (3): 107–113. doi: 10.1159/000440730Selvik H.A., Thomassen L., Bjerkreim A.T., Næss H. Cancer-associated stroke: The Bergen NORSTROKE study. Cerebrovasc. Dis. Extra, 2015; 5 (3): 107–113. doi: 10.1159/000440730Qureshi A.I., Malik A.A., Saeed O., Adil M.M., Rodriguez G.J., Suri M.F. Incident cancer in a cohort of 3,247 cancer diagnosis free ischemic stroke patients. Cerebrovasc. Dis., 2015; 39 (5-6): 262–268. doi: 10.1159/000375154Qureshi A.I., Malik A.A., Saeed O., Adil M.M., Rodriguez G.J., Suri M.F. Incident cancer in a cohort of 3,247 cancer diagnosis free ischemic stroke patients. Cerebrovasc. Dis., 2015; 39 (5-6): 262–268. doi: 10.1159/000375154Haugnes H.S., Wethal T., Aass N., Dahl O., Klepp O., Langberg C.W., Wilsgaard T., Bremnes R.M., Fossе S.D. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J. Clin. Oncol., 2010; 28 (30): 4649–4657. doi: 10.1200/JCO.2010.29.9362Haugnes H.S., Wethal T., Aass N., Dahl O., Klepp O., Langberg C.W., Wilsgaard T., Bremnes R.M., Fossе S.D. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J. Clin. Oncol., 2010; 28 (30): 4649–4657. doi: 10.1200/JCO.2010.29.9362Ueki Y., Vögeli B., Karagiannis A., Zanchin T., Zanchin C., Rhyner D., Otsuka T., Praz F., Siontis G.C.M, Moro C., Stortecky S., Billinger M., Valgimigli M., Pilgrim T., Windecker S., Suter T., Räber L. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC CardioOncol., 2019; 1 (2): 145–155. doi: 10.1016/j.jaccao.2019.11.001Ueki Y., Vögeli B., Karagiannis A., Zanchin T., Zanchin C., Rhyner D., Otsuka T., Praz F., Siontis G.C.M, Moro C., Stortecky S., Billinger M., Valgimigli M., Pilgrim T., Windecker S., Suter T., Räber L. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC CardioOncol., 2019; 1 (2): 145–155. doi: 10.1016/j.jaccao.2019.11.001Potts J.E., Iliescu C.A., Lopez Mattei J.C., Martinez S.C., Holmvang L., Ludman P., de Belder M.A., Kwok C.S., Rashid M., Fischman D.L., Mamas M.A. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur. Heart J., 2019; 40 (22): 1790–1800. doi: 10.1093/eurheartj/ehy769Potts J.E., Iliescu C.A., Lopez Mattei J.C., Martinez S.C., Holmvang L., Ludman P., de Belder M.A., Kwok C.S., Rashid M., Fischman D.L., Mamas M.A. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur. Heart J., 2019; 40 (22): 1790–1800. doi: 10.1093/eurheartj/ehy769Lyon A.R., Lуpez-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J., 2022; 43 (41): 4229–4361. doi: 10.1093/eurheartj/ehac244Lyon A.R., Lуpez-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J., 2022; 43 (41): 4229–4361. doi: 10.1093/eurheartj/ehac244Gross C.M., Posch M.G., Geier C., Olthoff H., Krämer J., Dechend R., Dietz R., Ozcelik C. Subacute coronary stent thrombosis in cancer patients. J. Am. Coll. Cardiol., 2008; 51 (12): 1232–1233. doi: 10.1016/j.jacc.2007.11.061Gross C.M., Posch M.G., Geier C., Olthoff H., Krämer J., Dechend R., Dietz R., Ozcelik C. Subacute coronary stent thrombosis in cancer patients. J. Am. Coll. Cardiol., 2008; 51 (12): 1232–1233. doi: 10.1016/j.jacc.2007.11.061Bianco M., D’ascenzo F., Raposeiras Roubin S., Kinnaird T., Peyracchia M., Ariza-Solé A., Cerrato E., Manzano-Fernández S., Gravinese C., Templin C., Destefanis P., Velicki L., Luciano A., Xanthopoulou I., Rinaldi M., Rognoni A., Varbella F., Boccuzzi G., Omedè P., Montabone A., Bernardi A., Taha S., Rossini R., Durante A., Gili S., Magnani G., Autelli M., Grosso A., Blanco P.F., Giustetto C., Garay A. Quadri G., Queija B.C., Srdanovic I., Paz R.C., Fernández M.C., Pousa I.M., Gallo D., Morbiducci U., Dominguez-Rodriguez A., Lopez-Cuenca Á., Cequier A., Alexopoulos D., Iсiguez-Romo A., Pozzi R., Assi E.A., Valgimigli M. Comparative external validation of the PRECISEDAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Int. J. Cardiol., 2020; 301: 200–206. doi: 10.1016/j.ijcard.2019.11.132Bianco M., D’ascenzo F., Raposeiras Roubin S., Kinnaird T., Peyracchia M., Ariza-Solé A., Cerrato E., Manzano-Fernández S., Gravinese C., Templin C., Destefanis P., Velicki L., Luciano A., Xanthopoulou I., Rinaldi M., Rognoni A., Varbella F., Boccuzzi G., Omedè P., Montabone A., Bernardi A., Taha S., Rossini R., Durante A., Gili S., Magnani G., Autelli M., Grosso A., Blanco P.F., Giustetto C., Garay A. Quadri G., Queija B.C., Srdanovic I., Paz R.C., Fernández M.C., Pousa I.M., Gallo D., Morbiducci U., Dominguez-Rodriguez A., Lopez-Cuenca Á., Cequier A., Alexopoulos D., Iсiguez-Romo A., Pozzi R., Assi E.A., Valgimigli M. Comparative external validation of the PRECISEDAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Int. J. Cardiol., 2020; 301: 200–206. doi: 10.1016/j.ijcard.2019.11.132Bharadwaj A., Potts J., Mohamed M.O., Parwani P., Swamy P., Lopez-Mattei J.C., Rashid M., Kwok C.S., Fischman D.L., Vassiliou V.S., Freeman Ph., Michos E.D., Mamas M.A. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur. Heart J., 2020; 41 (23): 2183–2193. doi: 10.1093/eurheartj/ehz851Bharadwaj A., Potts J., Mohamed M.O., Parwani P., Swamy P., Lopez-Mattei J.C., Rashid M., Kwok C.S., Fischman D.L., Vassiliou V.S., Freeman Ph., Michos E.D., Mamas M.A. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur. Heart J., 2020; 41 (23): 2183–2193. doi: 10.1093/eurheartj/ehz851Duarte C.W., Lindner V., Francis S.A., Schoormans D. Visualization of cancer and cardiovascular disease co-occurrence with network methods. JCO Clin. Cancer Inform., 2017; 1: 1–12. doi: 10.1200/CCI.16.00071Duarte C.W., Lindner V., Francis S.A., Schoormans D. Visualization of cancer and cardiovascular disease co-occurrence with network methods. JCO Clin. Cancer Inform., 2017; 1: 1–12. doi: 10.1200/CCI.16.00071Milazzo V., Cosentino N., Campodonico J., Lucci C., Cardinale D., Cipolla C.M., Marenzi G. Characteristics, management, and outcomes of acute coronary syndrome patients with cancer. J. Clin. Med., 2020; 9 (11): 3642. doi: 10.3390/jcm9113642Milazzo V., Cosentino N., Campodonico J., Lucci C., Cardinale D., Cipolla C.M., Marenzi G. Characteristics, management, and outcomes of acute coronary syndrome patients with cancer. J. Clin. Med., 2020; 9 (11): 3642. doi: 10.3390/jcm9113642Ederhy S., Cohen A., Boccara F., Puymirat E., Aissaoui N., Elbaz M., Bonnefoy-Cudraz E., Druelles P., Andrieu S., Angoulvant D., Furber A., Ferrières J., Schiele F., Cottin Y., Simon T., Danchin N. FASTMI investigators. In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French registry on Acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort. Arch. Cardiovasc. Dis., 2019; 112 (11): 657–669. doi: 10.1016/j.acvd.2019.06.012Ederhy S., Cohen A., Boccara F., Puymirat E., Aissaoui N., Elbaz M., Bonnefoy-Cudraz E., Druelles P., Andrieu S., Angoulvant D., Furber A., Ferrières J., Schiele F., Cottin Y., Simon T., Danchin N. FASTMI investigators. In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French registry on Acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort. Arch. Cardiovasc. Dis., 2019; 112 (11): 657–669. doi: 10.1016/j.acvd.2019.06.012Gevaert S.A., Halvorsen S., Sinnaeve P.R., Sambola A., Gulati G., Lancellotti P., van der Meer P., Lyon A.R., Farmakis D., Lee G., Boriani G., Wechalekar A., Okines A., Asteggiano R. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. Eur. Heart J. Acute Cardiovasc. Care, 2021; 10 (8): 947–959. doi: 10.1093/ehjacc/zuab056Gevaert S.A., Halvorsen S., Sinnaeve P.R., Sambola A., Gulati G., Lancellotti P., van der Meer P., Lyon A.R., Farmakis D., Lee G., Boriani G., Wechalekar A., Okines A., Asteggiano R. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. Eur. Heart J. Acute Cardiovasc. Care, 2021; 10 (8): 947–959. doi: 10.1093/ehjacc/zuab056Pushparaji B., Donisan T., Balanescu D.V., Park J.K., Monlezun D.J., Ali A., Inanc I.H., Caballero J., Cilingiroglu M., Marmagkiolis K., Iliescu C. Coronary revascularization in patients with cancer. Curr. Treat. Options. Cardiovasc. Med., 2023; 25 (6): 143–158. doi: 10.1007/s11936-023-00982-9Pushparaji B., Donisan T., Balanescu D.V., Park J.K., Monlezun D.J., Ali A., Inanc I.H., Caballero J., Cilingiroglu M., Marmagkiolis K., Iliescu C. Coronary revascularization in patients with cancer. Curr. Treat. Options. Cardiovasc. Med., 2023; 25 (6): 143–158. doi: 10.1007/s11936-023-00982-9Yusuf S.W., Daraban N., Abbasi N., Lei X., Durand J.B., Daher I.N. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin. Cardiol., 2012; 35 (7): 443–450. doi: 10.1002/clc.22007Yusuf S.W., Daraban N., Abbasi N., Lei X., Durand J.B., Daher I.N. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin. Cardiol., 2012; 35 (7): 443–450. doi: 10.1002/clc.22007Pothineni N.V., Shah N.N., Rochlani Y., Saad M., Kovelamudi S., Marmagkiolis K., Bhatti S., Cilingiroglu M., Aronow W.S., Hakeem A. Temporal trends and outcomes of acute myocardial infarction in patients with cancer. Ann. Transl. Med., 2017; 5 (24): 482. doi: 10.21037/atm.2017.11.29Pothineni N.V., Shah N.N., Rochlani Y., Saad M., Kovelamudi S., Marmagkiolis K., Bhatti S., Cilingiroglu M., Aronow W.S., Hakeem A. Temporal trends and outcomes of acute myocardial infarction in patients with cancer. Ann. Transl. Med., 2017; 5 (24): 482. doi: 10.21037/atm.2017.11.29Roule V., Verdier L., Blanchart K., Ardouin P., Lemaitre A., Bignon M., Sabatier R., Alexandre J., Beygui F. Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and/or percutaneous coronary intervention. BMC Cardiovasc. Disord., 2020; 20 (1): 38. doi: 10.1186/s12872-020-01352-0Roule V., Verdier L., Blanchart K., Ardouin P., Lemaitre A., Bignon M., Sabatier R., Alexandre J., Beygui F. Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and/or percutaneous coronary intervention. BMC Cardiovasc. Disord., 2020; 20 (1): 38. doi: 10.1186/s12872-020-01352-0Iliescu C.A., Grines C.L., Herrmann J., Yang E.H., Cilingiroglu M., Charitakis K., Hakeem A., Toutouzas K.P., Leesar M.A., Marmagkiolis K. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista). Catheter Cardiovasc. Interv., 2016; 87 (5): E202–223. doi: 10.1002/ccd.26379Iliescu C.A., Grines C.L., Herrmann J., Yang E.H., Cilingiroglu M., Charitakis K., Hakeem A., Toutouzas K.P., Leesar M.A., Marmagkiolis K. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista). Catheter Cardiovasc. Interv., 2016; 87 (5): E202–223. doi: 10.1002/ccd.26379

The authors declare that there are no conflicts of interest present.